OTCPK:CVSC

Stock Analysis Report

Cardiovascular Sciences

Executive Summary

Cardiovascular Sciences Inc., a technology company, focuses on the development of medical products.

Snowflake

Fundamentals

Adequate balance sheet with weak fundamentals.

Risks

  • Cardiovascular Sciences has significant price volatility in the past 3 months.
  • Cardiovascular Sciences's last earnings update was 3815 days ago.
  • Cardiovascular Sciences is not covered by any analysts.
  • Cardiovascular Sciences is a small market cap stock, these often have low liquidity.

Share Price & News

How has Cardiovascular Sciences's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-97.0%

CVSC

1.1%

US Medical Equipment

-0.6%

US Market


1 Year Return

-90.0%

CVSC

9.9%

US Medical Equipment

0.6%

US Market

CVSC underperformed the Medical Equipment industry which returned 9.5% over the past year.

CVSC underperformed the Market in United States of America which returned 1.1% over the past year.


Share holder returns

CVSCIndustryMarket
7 Day-97.0%1.1%-0.6%
30 Day-97.0%0.6%2.2%
90 Day0%2.9%1.1%
1 Year-90.0%-90.0%10.8%9.9%2.9%0.6%
3 Year-90.0%-90.0%70.1%64.9%44.6%35.2%
5 Yearn/a138.9%111.8%61.9%44.2%

Price Volatility Vs. Market

How volatile is Cardiovascular Sciences's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Cardiovascular Sciences undervalued based on future cash flows and its price relative to the stock market?


In this section, we usually try to help investors determine whether Cardiovascular Sciences is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Cardiovascular Sciences has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.


Next Steps

Future Growth

How is Cardiovascular Sciences expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

22.5%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Cardiovascular Sciences has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Cardiovascular Sciences performed over the past 5 years?

0.2%

Historical Healthcare annual earnings growth


In this section we usually display a company’s past earnings and revenues to help investors visualise the trend through time. We also gauge the company’s performance by benchmarking its returns and growth to its industry peers and the wider market. However, Cardiovascular Sciences has not provided sufficient past data to assess its track record.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have historical data.


Next Steps

Financial Health

How is Cardiovascular Sciences's financial position?


In this section we usually analyse Cardiovascular Sciences's finance health to determine how well-positioned it is against times of financial distress, in particular, its ability to manage its cash and debt levels. Cardiovascular Sciences has not provided adequate balance sheet data, its financial health cannot be properly assessed as it.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have financial information.


Next Steps

  • Take a look at our analysis of CVSC’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • Investors tend to look at the financial health of a company this size in order to assess the sustainability of its current operations. While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website.
  • Financial health is measured at one point in time, so the latest financial report is the best representation of the company’s current financial status. Check when Cardiovascular Sciences's financial data was last updated here.
  • Explore more healthy companies in the Healthcare industry.

Dividend

What is Cardiovascular Sciences's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate Cardiovascular Sciences's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate Cardiovascular Sciences's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as Cardiovascular Sciences has not reported any payouts.

Unable to verify if Cardiovascular Sciences's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as Cardiovascular Sciences has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of Cardiovascular Sciences's salary, the management and board of directors tenure and is there insider trading?

14.7yrs

Average management tenure


CEO

Larry Hooper 0

0yrs

Tenure

0

Dr. Larry Hooper, M.D. serves as Chief Executive Officer of Cardiovascular Sciences, Inc. Dr. Hooper is a physician. He holds B.A. in Chemistry and Psychology from University of North Carolina at Chapel Hi ...


Management Age and Tenure

14.7yrs

Average Tenure

The average tenure for the Cardiovascular Sciences management team is over 5 years, this suggests they are a seasoned and experienced team.


Board Age and Tenure

16.7yrs

Average Tenure

69yo

Average Age

The average tenure for the Cardiovascular Sciences board of directors is over 10 years, this suggests they are a seasoned and experienced board.


Insider Trading

No 3 month open market individual insider trading information.


Ownership Breakdown


Management Team

  • Michael D'Apolito (66yo)

    President of Weight Loss & Wellness

    • Tenure: 16.2yrs
  • Byron Rambo (61yo)

    Chief Financial Officer

    • Tenure: 16.7yrs
  • Tim Murray

    President

    • Tenure: 14.7yrs
  • Brian Schneider

    Executive Vice President

    • Tenure: 13.6yrs
  • Sandy Williams

    Director of Operations

    • Tenure: 13.5yrs
  • Larry Hooper

    Chief Executive Officer

    • Tenure: 0yrs

Board Members

  • Harold Kestenbaum (69yo)

    Director

    • Tenure: 17.3yrs
  • John Martin (76yo)

    Director

    • Tenure: 11.6yrs
  • Byron Rambo (61yo)

    Chief Financial Officer

    • Tenure: 16.7yrs
  • Kenneth MacDonald

    Director of Concorde Resources Corp

    • Tenure: 0yrs

Company Information

Cardiovascular Sciences, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Cardiovascular Sciences, Inc.
  • Ticker: CVSC
  • Exchange: OTCPK
  • Founded:
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: US$16.000
  • Shares outstanding: 16.96m
  • Website: https://www.cvsciences.org

Location

  • Cardiovascular Sciences, Inc.
  • 3251 Progress Drive
  • Orlando
  • Florida
  • 32826
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
CVSCOTCPK (Pink Sheets LLC)YesCommon StockUSUSDOct 2001

Biography

Cardiovascular Sciences Inc., a technology company, focuses on the development of medical products. Its products include Anti Adhesion Technology products to prevent post surgical scarring; Pyruvate Therap ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/09/20 23:54
End of Day Share Price2019/09/17 00:00
Earnings2009/03/31
Annual Earnings2008/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.